Effects of venlafaxine and fluoxetine on lymphocyte subsets in patients with major depressive disorder: A flow cytometric analysis

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 34, Issue 1, 2010, Pages 70-75

  Başterzi, Ayşe Devrim ^a   Yazici, Kemal ^a   Buturak, Visal ^b   Çimen, Burak ^a   Yazici, Aylin ^a   Eskandari, Gülçin ^a   Tot Acar, Şenel ^a   Taşdelen, Bahar ^a  

^a MERSIN UNIVERSITY   (Turkey)

^b Adana Devlet Hastanesi   (Turkey)

Author keywords

CD16 56; CD45; Fluoxetine; Lymphocyte subsets; Venlafaxine

Indexed keywords

CD16 ANTIGEN; CD19 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; FLUOXETINE; HLA DR ANTIGEN; VENLAFAXINE;

ADULT; ARTICLE; B LYMPHOCYTE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG RESPONSE; FEMALE; FLOW CYTOMETRY; HELPER CELL; HUMAN; HUMAN CELL; IMMUNOREGULATION; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; RANDOMIZED CONTROLLED TRIAL; SUPPRESSOR CELL; T LYMPHOCYTE;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIGENS, CD; CASE-CONTROL STUDIES; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; FEMALE; FLOW CYTOMETRY; FLUOXETINE; HUMANS; LYMPHOCYTES; MALE; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 73649131918     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2009.09.025     Document Type: Article

References (73)

1. Akdemir A., Örsel S.D., Daǧ İ., Türkçapar M.H., İşcan N., and Özbay H. Reliability and validity of the Turkish version of the Hamilton Depression Rating Scale, its use in the clinical settings. J Psychiatr Psychol Psychopharmacol 4 (1996) 251-259
2. Andreoli A., Keller S., Rabaeus M., Zaugg L., Garrone G., and Taban C. Immunity, major depression and panic disorder comorbidity. Biol Psychiatry 31 (1992) 896-908
3. Artigas F., Nutt D.J., and Shelton R. Mechanism of action of antidepressants. Psychopharmacol Bull 2 (2002) 123-132
4. Brambilla F., Bellodi L., Perna G., Battaglia M., Sciuto G., Diafenia G., Petraglia F., Panerai A., and Sacerdote P. Psychoimmunoendocrine aspects of panic disorder. Neuropsychobiology 26 (1992) 12-22
5. Capuron L., and Dantzer R. Cytokines and depression: the need for a new paradigm. Brain Behav Immun 1 Supp l (2003) 119-124
6. Charles G., Machowski R., Brohee D., Wilmotte J., and Kennes B. Lymphocyte subsets in major depressive patients. Influence of anxiety and corticoadrenal overdrive. Neuropsychobiology 25 2 (1992) 94-98
7. Connor T.J., and Leonard B.E. Depression, stress and immunological activation: the role of cytokines in depressive disorders. Life Sci 62 (1998) 583-606
8. Dantzer R., O'Connor J.C., Freund G.G., Johnson R.W., and Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 9 (2008) 46-56
9. Denys D., Fluitman S., Kavelaars A., Heijnen C., and Westenberg H.G. Effects of paroxetine and venlafaxine on immune parameters in patients with obsessive compulsive disorder. Psychoneuroendocrinology 31 3 (2006) 355-360 [Apr]
10. Edgar V.A., Cremaschi G.A., Sterin-Borda L., and Genaro A.M. Altered expression of autonomic neurotransmitter receptors and proliferative responses in lymphocytes from a chronic mild stress model of depression: effects of fluoxetine. Brain Behav Immun 16 (2002) 333-350
11. Evans D.L., Pederson C.A., and Folds J.D. Major depression and immunity: preliminary evidence of decreased natural killer cell populations. Prog Neuropsychopharmacol Biol Psychiatry 12 (1988) 739-748
12. Evans D.L., Folds J.D., Petitto J.M., Golden R.N., Pedersen C.A., Corrigan M., et al. Circulating natural killer cell phenotypes in males and females with major depression: relation to cytotoxic activity and severity of depression. Arch Gen Psychiatry 49 (1992) 388-395
13. Evans D.L., and Charney D.S. Mood disorders and medical illness: a major public health problem. Biol Psychiatry 54 (2003) 177-180
14. Fazzino F., Obregón F., Morles M., Rojas A., Arocha L., Mata S., and Lima L. Taurine transporter in lymphocytes of patients with major depression treated with venlafaxine plus psychotherapy. Adv Exp Med Biol 643 (2009) 217-224
15. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV axis I Disorders (SCID-I), Clinical Version, 1st ed. American Psychiatric Press, Inc., Washington DC, London, England, 1997.
16. Frank M.G., Hendricks S.E., Johnson D.R., Wieseler J.L., and Burke W. Antidepressants augment natural killer cell activity: in vivo and in vitro. Biol Psychiatry 39 (1999) 18-24
17. Frick L.R., Palumbo M.L., Zappia M.P., Brocco M.A., Cremaschi G.A., and Genaro A.M. Inhibitory effect of fluoxetine on lymphoma growth through the modulation of antitumor T cell response by serotonin dependent and independent mechanisms. Biochem Pharmacol 75 (2008) 1817-1826
18. Fujigaki H., Saito K., Fujigaki S., Takemura M., Sudo K., Ishiguro H., et al. The signal transducer and activator of transcription 1 alpha and interferon regulatory factor 1 are not essential for the induction of indoleamine 2, 3-dioxygenase by lipopolysaccharide: involvement of p38 mitogen-activated protein kinase and nuclear factor-kappaB pathways, and synergistic effect of several proinflammatory cytokines. J Biochem 139 (2006) 655-662
19. Gladkevich A., Kauffman H.F., and Korf J. Lymphocytes as a neural probe: potential for studying psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 28 (2004) 559-576
20. Golden R.N., and Nicholas L. Antidepressant efficacy of venlafaxine. Depress Anxiety 12 Suppl 1 (2000) 45-49
21. Hellstrand K., and Hermodsson S. Enhancement of human natural killer cell cytotoxicity by serotonin: role of non-T/CD16C NK cells, accessory monocytes, and 5-HT1A receptors. Cell Immunol 127 (1990) 199-214
22. Herbert T.B., and Cohen S. Depression and immunity: a meta-analytic review. Psychol Bull 113 (1993) 472-486
23. Huntington N.D., and Tarlinton D.M. CD45: direct and indirect government of immune regulation. Immunol Lett 94 (2005) 67-74
24. Irwin M., Lacher U., and Caldwell C.L. Depression and reduced natural killer cytotoxicity: a longitudinal study of depressed patients and control subjects. Psychol Med 22 (1992) 1045-1050
25. Kohm A.P., and Sanders V. Norepinephrine and beta2-adrenergic receptor stimulation regulate CD4+ T and B lymphocyte function in vitro and in vivo. Pharmacol Rev 53 (2001) 487-525
26. Kubera M., Van Bockstaele D., and Maes M. Leukocyte subsets in treatment-resistant major depression. Pol J Pharmacol 51 (1999) 547-549
27. Kubera M., Lin A.H., Kenis G., Bosmans E., van Bockstaele D., and Maes M. Anti-inflammatory effects of antidepressants through suppression of the interferon-gamma/interleukin-10 production ratio. J Clin Psychopharmacol 21 (2001) 199-206
28. Kubera M., Kenis G., Bosmans E., Kajta M., Basta-Kaim A., Scharpe S., Budziszewska B., and Maes M. Stimulatory effect of antidepressants on the production of IL-6. Int Immunopharmacol 4 (2004) 185-192
29. Lang K., Drell T.L., Niggemann B., Zanker K.S., and Entschladen F. Neurotransmitters regulate the migration and cytotoxicity in natural killer cells. Immunol Lett 90 (2003) 165-172
30. Maes M. Evidence for an immune response in major depression: a review and a hypothesis. Prog Neuropsychopharmacol Biol Psychiatry 19 (1995) 11-38
31. Maes M., Lambrechts J., Bosmans E., Jacobs J., Suy E., Vandervorst C., et al. Evidence for a systemic immune activation during depression: results of leukocyte enumeration by flow cytometry in conjunction with monoclonal antibody staining. Psychol Med 22 (1992) 45-53
32. Maes M., Stevens W., DeClerck L., Bridts C., Peeters D., Schotte C., et al. Immune disorders in depression: higher T helper/T suppressor-cytotoxic cell ratio. Acta Psychiatr Scand 86 (1992) 423-431
33. Maes M., VanPlanken M., Stevens W.J., Peeters D., DeClerck L.S., Bridts C.H., Schotte C., and Cosyns P. Leukocytosis, monocytosis and neutrophilia: hallmarks of severe depression. J Psychiatric Res 26 (1992) 125-134
34. Maes M., Lambrechts J., Suy E., Vandervorst C., and Bosmans E. Absolute number and percentage of circulating natural killer, non-MHC-restricted T cytotoxic, and phagocytic cells in unipolar depression. Neuropsychobiology 29 (1994) 157-163
35. Maes M., Meltzer H.Y., Stevens W., Calabrese J., and Cosyns P. Natural killer cell activity in major depression: relation to circulating natural killer cells, cellular indices of the immune response, and depressive phenomenology. Prog Neuropsychopharmacol Biol Psychiatry 18 (1994) 717-730
36. Maes M., Smith R., and Scharpe S. The monocyte-T-lymphocyte hypothesis of major depression. Psychoneuroendocrinology 20 (1995) 111-116
37. Maes M., Kenis G., Kubera M., De Baets M., Steinbusch H., and Bosmans E. The negative immunoregulatory effects of fluoxetine in relation to the cAMP-dependent PKA pathway. Int Immunopharmacol 5 (2005) 609-618
38. Marazziti D., Ambrogi F., Vanacore R., Mignani V., Savino M., Palego L., Cassano G.B., and Akiskal H.S. Immune cell imbalance in major depression and panic disorder. Neuropsychobiology 26 (1992) 23-26
39. Maxeiner H.G., Rojewski M.T., Schmitt A., Tumani H., Bechter K., and Schmitt M. Flow cytometric analysis of T cell subsets in paired samples of cerebrospinal fluid and peripheral blood from patients with neurological and psychiatric disorders. Brain Behav Immun 23 (2009) 134-142
40. Miller A.H., Maletic V., and Raison C.L. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 65 (2009) 732-741
41. Mohl P.C., Huang L., Bowden C., Fischbach M., Vogtsberger K., and Talal N. Natural killer cell activity in major depression. Am J Psychiatry 144 (1987) 1619
42. Montgomery S.A., Baldwin D.S., Blier P., Fineberg N.A., Kasper S., Lader M., et al. Which antidepressants have demonstrated superior efficacy? A review of the evidence. Int Clin Psychopharmacol 22 (2007) 323-329
43. Müller N., Hofschuster E., Ackenheil M., Mempel W., and Eckstein R. Investigations of the cellular immunity during depression and the free interval: evidence for an immune activation in affective psychosis. Prog Neuropsychopharmacol Biol Psychiatry 17 (1993) 713-730
44. Natelson B.H., Denny T., Zhou X.D., LaManca J.J., Ottenweller J.E., Tiersky L., et al. Is depression associated with immune activation?. J Affect Disord 53 (1999) 179-184
45. Nunez M.J., Balboa J., Rodrigo E., Brenlla J., Gonzalez-Peteiro M., and Freire-Garabal M. Effects of fluoxetine on cellular immune response in stressed mice. Neurosci Lett 396 (2006) 247-251
46. Park E.J., Lee J.H., Chae J.H., Lee K.H., Han S.I., and Jeon Y.W. Natural killer T cells in patients with major depressive disorder. Psychiatr Res 144 (2006) 237-239
47. Pellegrino T.C., and Bayer B.M. Modulation of immune cell function following fluoxetine administration in rats. Pharmacol Biochem Behav 59 (1998) 151-157
48. Pellegrino T.C., and Bayer B.M. Role of central 5-HT(2) receptors in fluoxetine-induced decreases in T lymphocyte activity. Brain Behav Immun 16 (2002) 87-103
49. Perini G., Zara M., Carraro C., et al. Psychoimmunoendocrine aspects of panic disorder. Hum Psychopharmacol 10 (1995) 461-465
50. Rapaport M.H. Circulating lymphocyte phenotypic surface markers in anxiety disorder patients and normal volunteers. Biol Psychiatry 43 (1998) 458-463
51. Ravindran A.V., Griffiths J., Merali Z., and Anisman H. Lymphocyte subsets associated with major depression and dysthymia: modification by antidepressant treatment. Psychosom Med 57 (1995) 555-563
52. Ravindran A.V., Griffiths J., Merali Z., and Anisman H. Circulating lymphocyte subsets in major depression and dysthymia with typical or atypical features. Psychosom Med 60 (1998) 283-289
53. Rosenzweig-Lipson S., Beyer C.E., Hughes Z.A., Khawaja X., Rajarao S.J., Malberg J.E., Rahman Z., Ring R.H., and Schechter L.E. Differentiating antidepressants of the future: efficacy and safety. Pharmacol Ther 113 (2006) 134-153
54. Rothermundt M., Arolt V., Fenker J., Gutbrodt H., Peters M., and Kirchner H. Different immune patterns in melancholic and non-melancholic major depression. Eur Arch Psychiatry Clin Neurosci 251 (2001) 90-97
55. Rudolf S., Schlenke P., Broocks A., et al. Search for atypical lymphocytes in schizophrenia. World J Biol Psychiatry 5 (2004) 33-37
56. Schlatter J., Ortuno F., and Cervera-Enguix S. Lymphocyte subsets and lymphokine production in patients with melancholic versus nonmelancholic depression. Psychiatry Res 128 (2004) 259-265
57. Schleifer S.J., Keller S.E., and Bartlett J.A. Depression and immunity: clinical factors and therapeutic course. Psychiatry Res 18 (1999) 63-69
58. Schleifer S.J., Keller S.E., and Bartlet J.A. Panic disorder and immunity: few effects on circulating lymphocytes, mitogen response, and NK cell activity. Brain Behav Immun 16 (2002) 698-705
59. Scheifler S., Keller S., Scott B., and Vecchione J. Lymphocyte function in panic disorder. Biol Psychiatry 27 suppl 9A (1990) 66A
60. Schwarcz R., and Pellicciari R. Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities. J Pharmacol Exp Ther 303 (2002) 1-10
61. Seidel A., Arolt V., Hunstiger M., Rink L., Behnisch A., and Kirchner H. Increased CD56+ natural killer cells and related cytokines in major depression. Clin Immunol Immunopathol 78 (1996) 83-85
62. Smith R.S. The macrophage theory of depression. Med Hypotheses 35 (1991) 298-306
63. Surman O., Williams J., Sheehan D., Strom T., Jones K., and Coleman J. Immunological response to stress in agoraphobia and panic attacks. Biol Psychiatry 21 (1986) 768-774
64. Syvalahti E., Eskola J., Ruuskanen O., and Laine T. Nonsuppression of cortisol in depression and immune function. Prog Neuropsychopharmacol Biol Psychiatry 9 (1985) 413-422
65. Tan J., Town T., and Mullan M. CD45 inhibits CD40L-induced microglial activation via negative regulation of the Src/p44/42 MAPK pathway. J Biol Chem 275 (2000) 37224-37231
66. Tan J., Town T., Mori T., Wu Y., Saxe M., and Crawford F. Mullan M.CD45 opposes beta-amyloid peptide-induced microglial activation via inhibition of p44/42 mitogen-activated protein kinase. J Neurosci 20 (2000) 7587-7594
67. Tran P.V., Bymaster F.P., McNamara R.K., and Potter W.Z. Dual monoamine modulation for improved treatment of major depressive disorder. J Clin Psychopharmacol 23 (2003) 78-86
68. Urassa W.K., Mbena E.M., Swai A.B., Gaines H., Mhalu F.S., and Biberfeld G. Lymphocyte subset enumeration in HIV seronegative and HIV-1 seropositive adults in Dar es Salaam, Tanzania: determination of reference values in males and females and comparison of two flow cytometric methods. J Immunol Methods 277 (2003) 65-74
69. Wahle M., Stachetzki U., Krause A., Pierer M., Hantzschel H., and Baerwald C.G. Regulation of beta 2-adrenergic receptors on CD4 and CD8 positive lymphocytes by cytokines in vitro. Cytokine 16 (2001) 205-209
70. Wang Y.M., Xu F., Gainetdinov R.R., and Caron M.G. Genetic approaches to studying norepinephrine function: knockout of the mouse norepinephrine transporter gene. Biol Psychiatry 46 (1999) 1124-1130
71. Williams B.W. A structured interview guide for Hamilton depression rating scale. Arch Gen Psychiatry 45 (1978) 742-747
72. Yazi{dotless}ci{dotless} M.K., Demir B., Tanri{dotless}verdi N., Karaoǧlu E., and Yolaç P. Hamilton Anxiety Rating Scale: interrater reliability and validity study. Turk Psikiyatri Derg 9 (1998) 114-117
73. Zhu Y., Hou H., Nikolic W.V., Ehrhart J., Rrapo E., Bickford P., et al. CD45RB is a novel molecular therapeutic target to inhibit Abeta peptide-induced microglial MAPK activation. PLoS One 3 (2008) e2135